Make acceleration achievable
A faster IND, NDA, BLA, or other submission requires more than a compressed date. Define cross-functional responsibilities, handoffs, and dependencies across regulatory, clinical, data management, preclinical, CMC, and medical writing teams. Agree with executives on budgets, priorities, and acceptable risk.
Explore options without losing focus
Identify additional capacity and specialist expertise, document assumptions, and evaluate acceleration scenarios with the functions affected. Keep optional analysis from displacing essential submission work.
In one startup engagement, scenario planning supported a decision to pursue an Australian clinical trial application before a U.S. IND. That was a program-specific choice, not a general recommendation or a reported approval outcome. The broader principle is to compare viable routes systematically and maintain an integrated plan that reflects the selected strategy.